ICTM logo
BLADDER NEOCT IPD
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data
Is it helpful to give chemotherapy before surgery to people with bladder cancer?
What was this study about?

Around the world, more than 100,000 people are diagnosed with bladder cancer every year. Most of these are men. Sometimes the cancer spreads, but stays within the bladder - this is called invasive bladder cancer. Doctors usually treat this type of bladder cancer with surgery (to try to remove the tumour) and/or radiotherapy.

We did a systematic review and meta-analysis of individual patient data, looking at whether it is helpful to give chemotherapy before surgery and/or radiotherapy to people with invasive bladder cancer. It brought together information from similar randomised controlled trials. These trials compared what happened to people who had been given chemotherapy before surgery and/or radiotherapy with those who had only had surgery and/or radiotherapy.

Who was included?

Patients with invasive bladder cancer who took part in randomised controlled trials comparing what happened to people who had been given chemotherapy before surgery and/or radiotherapy with those who had only had surgery and/or radiotherapy. The study brought together 11 trials from all over the world. These trials included over 3000 patients with bladder cancer.

What difference did this study make?

This study found that giving platinum-based chemotherapy before surgery and/or radiotherapy helped people with locally advanced bladder cancer to live longer.

Contact details

When did it take place?

This study was published in 2005. The trials included were carried out up to 2002.

Where did it take place?

The study was carried out by the Medical Research council in the UK, but brought together results of trials from around the world.

Who funded the study?

This study was funded by the Medical Research Council.

Further information


Type of study:
Meta-analyses
Status:
Closed
Study start date:

Related Publications

Advanced Bladder Cancer (ABC) Meta-analysis Collaboratio.

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. European Urology. 2005; 48:202-206

Ahmed, H.U., El-Shater Bosaily, A., Brown, L.C., Gabe, R., Kaplan, R., Parmar, M.K., Collaco-Moraes, Y., Ward, K., Hindley, R.G., Freeman, A., Kirkham, A.P., Oldroyd, R., Parker, C., Emberton, M., Promis study gro.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389:815-822

Cafferty, F.H., Coyle, C., Rowley, S., Berkman, L., MacKensie, M., Langley, R.

Co-enrolment of participants into multiple cancer trials: benefits and challenges. Clinical Oncology. 2017; 29:e126-e133

Gillessen, S., Attard, G., Beer, T.M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B.H., Clarke, N., Daugaard, G., Davis, I.D., de Bono, J., Dos Reis, R B., Drake, C.G., Eeles, R., Efstathiou, E., Evans, C.P., Fanti, S., Feng, F., Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C.S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A.K., Morris, M.J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A.R., Parker, C., Pritchard, C.C., Roach, M., Rubin, M.A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T., Omlin, .

Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. European Association of Urololgy. 2017.

James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Ritchie, A.W.S., Amos, C.L., Gilson, C., Jones, R.J., Matheson, D., Millman, R., Attard, G., Chowdhury, S., Cross, W.R., Gillessen, S., Parker, C.C., Russell, J.M., Berthold, D.R., Brawley, C., Adab, F., Aung, S., Birtle, A.J., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E., Hingorani, M., Hoskin, P.J., Lester, J.F., Malik, Z.I., McKinna, F., McPhail, N., Money-Kyrle, J., O'Sullivan, J., Parikh, O., Protheroe, A., Robinson, A., Srihari, N.N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M.K.B., Sydes, M.R., Stampede Investigato.

Abiraterone for prostate cancer not previously treated with hormone therapy. The New England Journal of Medicine. 2017.